Week In Review: CICC Capital Closes $229 Million China Fund For Biologics

CICC Capital closed a $229 million investment fund for biologics, with investments coming mainly from Chinese organizations inside and outside the biopharma industry. Some of the money will go to companies making COVID-19 vaccines and therapies.